| 1 |
35022783 | A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. | 2022 Mar 14 |
1 |
| 2 |
34497544 | Magnetic Resonance Spectroscopy in the Ventral Tegmental Area Distinguishes Responders to Suvorexant Prior to Treatment: A 4-Week Prospective Cohort Study. | 2021 |
1 |
| 3 |
34933185 | Blocking the orexin system following therapeutic exposure promoted between session habituation, but not PTSD symptom reduction. | 2021 Dec 14 |
1 |
| 4 |
32224066 | Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice. | 2020 Jul |
1 |
| 5 |
32669442 | Structure-based development of a subtype-selective orexin 1 receptor antagonist. | 2020 Jul 28 |
1 |
| 6 |
30619717 | Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus. | 2019 Mar |
1 |
| 7 |
29289556 | Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. | 2018 Jun |
2 |
| 8 |
27860547 | The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. | 2017 Jan 6 |
1 |
| 9 |
27909991 | The Role of Orexins/Hypocretins in Alcohol Use and Abuse. | 2017 |
1 |
| 10 |
28584695 | Neuroendocrine, Autonomic, and Metabolic Responses to an Orexin Antagonist, Suvorexant, in Psychiatric Patients with Insomnia. | 2017 Mar-Apr |
1 |
| 11 |
28945327 | Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia. | 2017 Dec |
1 |
| 12 |
28994603 | Suvorexant: scientifically interesting, utility uncertain. | 2017 Dec |
1 |
| 13 |
26317591 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. | 2016 Jan 28 |
1 |
| 14 |
26864332 | In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. | 2016 Oct |
2 |
| 15 |
27253658 | Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. | 2016 Aug |
2 |
| 16 |
27390287 | Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. | 2016 Oct 6 |
1 |
| 17 |
25397996 | Suvorexant: something new for sleep? | 2015 Feb |
1 |
| 18 |
25969666 | Suvorexant: The first orexin receptor antagonist to treat insomnia. | 2015 Apr-Jun |
2 |
| 19 |
24592206 | Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. | 2014 |
1 |
| 20 |
24680372 | Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. | 2014 May |
2 |
| 21 |
25197807 | Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. | 2014 Oct 1 |
1 |
| 22 |
25227290 | Suvorexant: first global approval. | 2014 Oct |
2 |
| 23 |
23359095 | Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. | 2013 Feb |
1 |
| 24 |
22725839 | Enantioselective synthesis of a dual orexin receptor antagonist. | 2012 Jul 6 |
1 |
| 25 |
22920041 | Update on emerging drugs for insomnia. | 2012 Sep |
2 |
| 26 |
23024835 | ACS chemical neuroscience molecule spotlight on Suvorexant. | 2012 Sep 19 |
1 |
| 27 |
21528938 | Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305). | 2011 Jun 1 |
4 |